J. Chen

机构：Xinjiang Medical University, Shanghai Jiao Tong University, Shanghai Mental Health Center, First Affiliated Hospital of Xinjiang Medical University, Shanghai University of Traditional Chinese Medicine, Second Affiliated Hospital of Dalian Medical University, Hunan Cancer Hospital, Fuzhou Second Hospital, China Communications Construction Company (China), Yueyang Hospital, Shanghai Traditional Chinese Medicine Hospital, Yunnan Investment Group (China), Changsha University of Science and Technology

发表论文 58 篇 · 总被引 306 次 · h-index 10

代表论文

• Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 17)
• Stress and deformation response of pipe jacking in upper-soft and lower-hard strata: A case study in Changsha (2024 · Engineering Failure Analysis · 被引 13)
• OA01.03 Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial (2023 · Journal of Thoracic Oncology · 被引 12)
• Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study (2024 · Experimental Hematology and Oncology · 被引 9)
• Causal Effects of Inflammatory Cytokines on Bipolar Disorder: A Bidirectional Two‐Sample Mendelian Randomization Study (2025 · Brain and Behavior · 被引 2)
• 61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study (2024 · ESMO Open · 被引 2)